Clinical Trial Update: To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF) [Phase 1, Phase 2]

View source ↗

Summary

This update notes that a Phase 1/Phase 2 study evaluating different doses of SAR156597 in Idiopathic Pulmonary Fibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• SAR156597

Snippet

Sponsor: Sanofi | Conditions: Idiopathic Pulmonary Fibrosis | Phase 1, Phase 2 | Status: COMPLETED